Dynavax Technologies (DVAX) Stock: Buy, Sell, or Hold?
$15.50
+0.00 (+0.00%)
â˛
5d:
+0.06%
30d:
+0.58%
90d:
+41.04%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: May 13, 2026
0d
Protect DVAX Gains
Updated Feb 9, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (46%)
Quality Score
48/100
Position
FAIR
Forward P/E & Valuation
47.0x
FAIR
vs 41.0x historical avg
Wall Street Target
$22.00
+41.9% upside
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$15.46 / $15.59
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: DVAX is fairly priced but lacks strong directional signals. At 4.6% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Get Alerted When DVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$11.56
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$7.18
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DVAX is currently trading at $15.50, which is considered fair based on recent price action. From a valuation perspective, the stock is trading at a premium (Forward PE: 47.0) compared to its historical average (41.0). At these levels, the market is pricing in 4.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DVAX is in a strong uptrend. The price is currently testing key support at $15.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DVAX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.00 (+41.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DVAX is in a strong uptrend. The price is currently testing key support at $15.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DVAX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.00 (+41.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
48/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
46.2%
Trading Range & Key Levels
Support Level
$15.46
Resistance Level
$15.59
Current Trend
Strong Uptrend
Technical data as of
Feb 9, 2026
Protect Your Profits
DVAX is technically overbought (RSI 75). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanQuantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: Trading 41.9% below Wall St target ($22.00)
- NEUTRAL: Market pricing in 4.6% annual earnings growth - fairly valued
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
46.97
Wall Street Target
$22.00
(+41.9%)
Revenue Growth (YoY)
17.7%
Earnings Growth (YoY)
69.3%
Profit Margin
-13.1%
Valuation Premium vs History
+4.6% premium
PE vs Historical
47.0 vs 41.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.6%
(market-implied from PE analysis)
1-Year Target
$16.21
(+5%)
2-Year Target
$16.96
(+9%)
3-Year Target
$17.74
(+14%)
3-Yr Target (if PE normalizes)
(PE: 47â41)
PE COMPRESSION
$15.48
(0%)
Earnings growth offset by PE compression
Share DVAX Analysis
Share this live DVAX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (DVAX)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Feb 6, 2026
Daily AI digest
AI Retail Discussion Summary:
A bullish sentiment prevails on StockTwits regarding $DVAX, with traders referencing potential alignments with TrumpRX and Dr. Oz's endorsement of cost savings from pills.
Key Retail Themes:
TrumpRX alignment
Dr. Oz endorsement
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 5:13 AM ET
Data refreshes hourly during market hours. Next update: 6:13 AM
Data refreshes hourly during market hours. Next update: 6:13 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 41 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 60 BUY |
|
TEVA
Teva Pharma Industries LâĻ |
STRONG BUY
15 analysts |
$49 | 36 SELL |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 51 HOLD |
Advanced DVAX Option Strategies
Professional options setups generated by AI based on today's DVAX price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive DVAX Research Pages
